CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 175 filers reported holding CLOVIS ONCOLOGY INC in Q3 2020. The put-call ratio across all filers is 0.94 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $106,000 | -53.3% | 15,062 | -68.2% | 0.00% | – |
| Q4 2020 | $227,000 | -16.8% | 47,299 | +0.9% | 0.00% | – |
| Q3 2020 | $273,000 | -13.6% | 46,889 | +0.0% | 0.00% | – |
| Q2 2020 | $316,000 | +6.0% | 46,878 | +0.1% | 0.00% | – |
| Q1 2020 | $298,000 | -64.7% | 46,811 | -42.3% | 0.00% | -100.0% |
| Q4 2019 | $845,000 | +78.6% | 81,089 | -32.6% | 0.00% | 0.0% |
| Q3 2019 | $473,000 | -73.6% | 120,276 | 0.0% | 0.00% | -50.0% |
| Q2 2019 | $1,789,000 | -29.7% | 120,276 | +1.1% | 0.00% | 0.0% |
| Q1 2019 | $2,545,000 | +138.5% | 118,982 | +100.2% | 0.00% | +100.0% |
| Q4 2018 | $1,067,000 | -38.9% | 59,431 | 0.0% | 0.00% | -50.0% |
| Q3 2018 | $1,745,000 | -34.2% | 59,431 | +1.9% | 0.00% | -33.3% |
| Q2 2018 | $2,651,000 | +4.7% | 58,306 | +21.6% | 0.00% | 0.0% |
| Q1 2018 | $2,532,000 | -22.4% | 47,961 | 0.0% | 0.00% | -25.0% |
| Q4 2017 | $3,261,000 | +48.6% | 47,961 | +80.1% | 0.00% | +33.3% |
| Q3 2017 | $2,195,000 | – | 26,633 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
| Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
| Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
| Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
| NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
| Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
| HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
| Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
| Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
| Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |